Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure.
Our previous study showed that static handgrip caused increases in the plasma adrenomedullin (ADM) both in patients with heart failure (HF) and healthy subjects. The present study was designed to determine the role of the sympathetic nervous system in mediating plasma ADM changes during handgrip in patients with HF. Twelve male HF patients (II class NYHA) treated with carvedilol, a non-selective adrenergic blocker (TC) and 12 patients untreated with carvedilol (UC) performed two 3-min bouts of static handgrip at 30% of maximal voluntary contraction, alternately with each hand. At the end of both exercise bouts and in 5 min of the recovery period, plasma ADM and catecholamines were determined. In addition, heart rate, blood pressure and stroke volume (SV) were measured. The baseline plasma ADM, noradrenaline (NA) and adrenaline (A) levels were similar in the two groups of patients, while SV was higher (P<0.05) in TC than in UC. During exercise plasma ADM concentrations were lower (P<0.05) in TC than in UC, but the handgrip-induced increases in plasma ADM did not differ between the groups. Plasma ADM correlated with NA concentrations (r = 0.764) and with SV (r = -0.435) and increases in plasma ADM expressed as percentage of baseline values correlated with those of plasma NA (r = 0.499), diastolic BP (r = 0.550) and total peripheral resistance (r = 0.435). The study suggests that the sympathetic nervous system may be involved in the stimulation of ADM secretion during static exercise either directly or by changes in the haemodynamic response.
Krzemiński
K
K
Department of Applied Physiology, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. krzem@cmdik.pan.pl
Nazar
K
K
Cybulski
G
G
Mikulski
T
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D053607:Adrenomedullin / Q000097:blood* / Q000187:drug effects*; D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002227:Carbazoles / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D000077261:Carvedilol; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D004837:Epinephrine / Q000097:blood; D005080:Exercise Test; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011412:Propanolamines / Q000627:therapeutic use*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D053607:Adrenomedullin; D009638:Norepinephrine; D004837:Epinephrine